Legend Biotech has been granted a non-exclusive worldwide license by MaxCyte to utilize their Flow Electroporation® technology and ExPERT™ platform in the development of cell-based therapeutic products. This agreement will enable Legend Biotech to leverage MaxCyte’s expertise in non-viral cell engineering and clinical manufacturing to create a diverse portfolio of cell therapies that strengthen patients’ immune systems and combat disease.
MaxCyte’s president and CEO, Maher Masoud, expressed excitement about supporting Legend Biotech’s non-viral engineered cell therapy program as they expand their portfolio with new delivery modalities. He noted that MaxCyte’s global infrastructure will provide technical, scientific, and regulatory support to advance Legend Biotech’s non-viral engineered therapeutic pipeline worldwide.
Ying Huang, PhD, CEO of Legend Biotech, stated that MaxCyte’s clinical manufacturing platform, non-viral cell engineering technology, and regulatory expertise will play a crucial role in supporting the development of their product pipeline across various cell types and modalities. She emphasized that this partnership will enable them to transform the treatment landscape by creating a diverse portfolio of cell therapies that strengthen patients’ immune systems and combat disease.